At the 1st Cyprus Oncology Conference in Nicosia, Dr. Papadatos-Pastos delivered a compelling presentation on the role of systemic therapies in optimizing treatment outcomes for oligometastatic non-small cell lung cancer (NSCLC). He highlighted the importance of chemotherapy, along with the latest advancements in targeted therapies and immunotherapy, emphasizing their role in enhancing long-term disease control.
Dr. Papadatos-Pastos discussed recent clinical data supporting the integration of systemic treatments with local therapies such as surgery and radiotherapy. His insights contributed to a broader understanding of personalized treatment approaches.
Following his presentation, he participated in a prestigious panel discussion alongside highly esteemed oncology experts from the UK, US, and Europe, engaging in thought-provoking discussions on best practices and emerging trends in managing oligometastatic lung cancer.
Dr. Papadatos-Pastos at the 1st Cyprus Oncology Conference in Nicosia
Treating Oligometastatic Non-Small Cell Lung Cancer: A Multidisciplinary Approach – New Hope For Lung Cancer Patients in 2025
Oligometastatic NSCLC is a unique stage where cancer has spread but remains limited to a few sites, offering a potential long-term disease control strategy through a combination of systemic therapy, surgery, and radiotherapy. Managing such cases requires a highly specialized multidisciplinary team (MDT) to ensure patients receive personalized, evidence-based treatment.
Dr. Papadatos-Pastos, an experienced member of five lung cancer MDTs and Co-Chair of the London Clinic Lung Cancer MDT, plays a key role in guiding treatment decisions, ensuring integration of systemic and local therapies.
Essential Diagnostic Steps:
- PET-CT scan for accurate staging, identifying active metastatic disease.
- MRI brain to detect asymptomatic metastases, influencing treatment decisions.
- Full molecular profiling to tailor systemic therapy, testing for EGFR, ALK, PD-L1 and other biomarkers.
Treatment Strategies:
- Systemic Therapy: Immunotherapy (e.g., pembrolizumab), targeted therapy (e.g., osimertinib for EGFR mutations), or chemotherapy.
- Local Therapy: Surgery or stereotactic body radiotherapy (SBRT) for select cases.
Combining systemic and local therapies has shown promising survival benefits. A highly experienced MDT is essential for tailored treatment decisions, optimizing outcomes and improving patient survival in oligometastatic NSCLC.